Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.4 USD | -5.65% | +7.45% | +150.37% |
11/04 | Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target | MT |
03/04 | Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer | CI |
Valuation
Fiscal Period: December | 2024 | 2025 | 2026 |
---|---|---|---|
Capitalization 1 | 326.9 | - | - |
Enterprise Value (EV) 1 | 326.9 | 326.9 | 326.9 |
P/E ratio | -6.27 x | -6.95 x | -6.44 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | - | - | - |
EV / FCF | -6.33 x | -5.34 x | -4.58 x |
FCF Yield | -15.8% | -18.7% | -21.8% |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 11,930 | - | - |
Reference price 2 | 27.40 | 27.40 | 27.40 |
Announcement Date | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | - | - | - |
EBITDA | - | - | - | - |
EBIT 1 | - | -49.57 | -56.9 | -65.47 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -51.13 | -55.5 | -65.26 |
Net income 1 | -53.74 | -51.13 | -55.5 | -65.26 |
Net margin | - | - | - | - |
EPS 2 | -7.410 | -4.370 | -3.945 | -4.255 |
Free Cash Flow 1 | - | -51.61 | -61.26 | -71.31 |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 27/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | -11.95 | -12.24 | -12.54 | -12.85 | -13.68 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -14.92 | -11.71 | -12.06 | -12.44 | -13.68 |
Net income 1 | -14.92 | -11.71 | -12.06 | -12.44 | -13.68 |
Net margin | - | - | - | - | - |
EPS 2 | -1.415 | -0.9800 | -1.005 | -1.035 | -0.8000 |
Dividend per Share | - | - | - | - | - |
Announcement Date | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow 1 | - | -51.6 | -61.3 | -71.3 |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex 1 | - | 2.67 | 2.81 | 3.42 |
Capex / Sales | - | - | - | - |
Announcement Date | 27/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+150.37% | 327M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-10.07% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- QTTB Stock
- Financials Q32 Bio Inc.